ANDA 202882, held by Hetero Labs Ltd V. Pantoprazole Sodium.
As of Nov 16, 2026, ANDA 202882 (Pantoprazole Sodium), held by Hetero Labs Ltd V, was first approved by FDA on Sep 10, 2014, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2014 | Original application | Approved | None posted |
| Pantoprazole SodiumEQ 20MG BASE · tablet, delayed release;oral | Pantoprazole Sodium | Rx |
| Pantoprazole SodiumEQ 40MG BASE · tablet, delayed release;oral | Pantoprazole Sodium | Rx |
| Jun 26, 2017 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 18, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Mar 18, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 10, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters